New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
10:23 EDTARGSArgos Therapeutics IPO indicated to open $9.40
Argos Therapeutics (ARGS) priced 5.63M shares at $8.00. Piper Jaffray, Stifel and JMP Securities acted as joint book running managers for the offering.
News For ARGS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
16:10 EDTARGSArgos Therapeutics provides 2015 anticipated milestones
The following are expected in 2015: Full enrollment and randomization in the phase 3 ADAPT trial for AGS-003 in mRCC expected by the end of second quarter 2015; Interim data analyses from the ADAPT trial by the IDMC expected in second quarter at approximately 25% of events and late 2015 at approximately 50% of events; Investigator-initiated phase 2 trials with AGS-003 in other tumor types and in other RCC settings, including early stage RCC and non-clear cell mRCC, planned for 2015; Continue investigator-initiated phase 2 adult eradication trial for AGS-004 in HIV; investigator-initiated phase 2 pediatric trial planned for second half of 2015; Continue the build-out and equipping of Argos' automated commercial manufacturing facility.
16:09 EDTARGSArgos Therapeutics reports Q4 EPS (83c), consensus (73c)
Subscribe for More Information
March 26, 2015
10:04 EDTARGSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:40 EDTARGSArgos Therapeutics initiated with a Buy at Roth Capital
Target $21.
March 25, 2015
07:16 EDTARGSPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use